Description:
Unlock comprehensive insights with Kalorama Information’s extensive 1500+ page report, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 15th Edition. This indispensable resource, published in 2022 and updated with an addendum chapter in March 2023, provides exhaustive market sizing and forecasting for every segment of the IVD industry.
Report Highlights:
- Comprehensive Market Analysis:
- Detailed market sizing and growth projections for the in vitro diagnostics (IVD) industry.
- Insightful forecasts over the next five years, highlighting growth trends, market dynamics, and emerging opportunities.
- Industry Segmentation:
- Thorough examination of various IVD market segments, identifying hot and cold areas.
- Analysis of key players and companies poised to benefit from market trends.
Key Insights:
- Vendor Reporting and Activities:
- In-depth analysis based on vendor reports, interviews, and global vendor activities.
- Insights into strategic moves, product launches, and innovations by leading IVD companies.
- Global Perspective:
- Comprehensive coverage of the global IVD market, offering regional insights and market dynamics.
- Detailed examination of market trends across North America, Europe, Asia Pacific, and other regions.
Why This Report is Essential:
Kalorama Information’s The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 15th Edition is like buying ten reports in one volume. This resource equips stakeholders with detailed insights and forecasts necessary for strategic planning and market positioning in the dynamic IVD industry. Whether you are an industry veteran or a newcomer, this report provides the knowledge and data required to navigate and thrive in the IVD market.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Clinical Diagnostic Revenues of Selected Top 20 IVD Companies*, 2021 and estimated 2022 ($ millions)
| Company | 2021 | 2022, estimated | % Change (2021-2022) |
| Abbott Diagnostics | $XX Million | $XX Million | XX% |
| Roche (all) | $XX Million | $XX Million | XX% |
| Danaher (all) | $XX Million | $XX Million | XX% |
| Siemens Healthineers | $XX Million | $XX Million | XX% |
| Thermo Fisher | $XX Million | $XX Million | XX% |
| Illumina | $XX Million | $XX Million | XX% |
| Becton Dickinson | $XX Million | $XX Million | XX% |
| bioMerieux | $XX Million | $XX Million | XX% |
| Sysmex Corporation | $XX Million | $XX Million | XX% |
| Dexcom | $XX Million | $XX Million | XX% |
| Hologic | $XX Million | $XX Million | XX% |
| Quidel | $XX Million | $XX Million | XX% |
| Werfen | $XX Million | $XX Million | XX% |
| Exact Sciences | $XX Million | $XX Million | XX% |
| Ortho Clinical Diagnostics | $XX Million | $XX Million | XX% |
| PerkinElmer | $XX Million | $XX Million | XX% |
| DiaSorin | $XX Million | $XX Million | XX% |
| Bio-Rad Laboratories | $XX Million | $XX Million | XX% |
| Agilent | $XX Million | $XX Million | XX% |
| QIAGEN | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | XX% |
*Note: Public companies
Source; Kalorama Information
